FDA orders all GLP-1 drug labels to warn of a rare eye condition that can cause vision loss
The FDA said an analysis of 126 clinical trials with 134,253 patients found 6.4 NAION cases per 100,000 person-years among patients taking GLP-1 drugs, compared with 3.8 among those on placebo or other glucose-lowering drugs. Its real-world study found a higher risk than with DPP-4 inhibitors but no statistically significant difference from SGLT-2 inhibitors, the agency said.
Novo Nordisk told CNBC it believes the data do not establish a cause-and-effect relationship. CNBC noted that European regulators flagged the risk for semaglutide in June 2025.
Why it matters: The FDA said NAION cases have been reported for all currently marketed GLP-1 products, a class widely used for type 2 diabetes and weight loss. The agency told patients to contact a health care professional right away about sudden vision changes.
References
- FDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Increased Risk of Rare But Serious Eye ConditionU.S. Food and Drug Administration · fda.gov · 2026-11-10
- FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, ZepboundCNBC · cnbc.com · 2026-11-10